Jump to main content
Jump to site search

Issue 3, 2016
Previous Article Next Article

Tetrahydro-pyrimido-indoles as selective LIMK inhibitors: synthesis, selectivity profiling and structure–activity studies

Author affiliations

Abstract

Extensive structure–activity studies on three different modification sites resulted in a series of LIM kinase inhibitors, containing a novel tricyclic hinge-binding motif based on the pyrrolopyrimidine scaffold. The compounds display a superior selectivity profile and significantly increased on-target activity compared to the former clinical candidate LX7101 (Lexicon Pharmaceuticals). Additionally, a soft drug approach to yield locally active analogues was successfully implemented.

Graphical abstract: Tetrahydro-pyrimido-indoles as selective LIMK inhibitors: synthesis, selectivity profiling and structure–activity studies

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 Oct 2015, accepted on 07 Dec 2015 and first published on 10 Dec 2015


Article type: Research Article
DOI: 10.1039/C5MD00473J
Author version
available:
Download author version (PDF)
Citation: Med. Chem. Commun., 2016,7, 478-483
  •   Request permissions

    Tetrahydro-pyrimido-indoles as selective LIMK inhibitors: synthesis, selectivity profiling and structure–activity studies

    J. Alen, A. Bourin, S. Boland, J. Geraets, P. Schroeders and O. Defert, Med. Chem. Commun., 2016, 7, 478
    DOI: 10.1039/C5MD00473J

Search articles by author

Spotlight

Advertisements